ABVC BioPharma, Inc. Share Price
ABVCABVC BioPharma, Inc. Stock Performance
Open $1.76 | Prev. Close $1.69 | Circuit Range N/A |
Day Range $1.69 - $1.76 | Year Range $0.40 - $5.43 | Volume 1,106 |
Average Traded $1.72 |
ABVC BioPharma, Inc. Share Price Chart
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is headquartered in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
ABVC BioPharma, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
06-Feb-26 | $1.76 | $1.77 | +10.28% |
05-Feb-26 | $1.77 | $1.60 | -15.08% |
04-Feb-26 | $1.89 | $1.89 | +0.00% |
03-Feb-26 | $1.94 | $1.89 | +0.27% |
02-Feb-26 | $2.00 | $1.89 | -7.10% |
30-Jan-26 | $2.03 | $2.03 | -1.02% |
29-Jan-26 | $2.03 | $2.05 | +0.49% |